Relmada Therapeutics (RLMD) Raises $160 Million as NDV-01 Bladder Cancer Data Set Up Phase 3
CORAL GABLES, Fla., March 9, 2026, 09:04 EDT Relmada Therapeutics plans to pull in roughly $160 million through a private placement, the company said Monday, after releasing year-long mid-stage trial data backing a move into late-stage development for NDV-01, its investigational bladder cancer drug. The round, oversubscribed and set at $4.75 per share, is expected to close around March 11.